{"entity":{"id":"ifupinostat","kind":"drug","name":"Ifupinostat","aka":["Ifupinostat Hydrochloride","BEBT-908 for Injection"],"tldr":"Ifupinostat is an experimental investigational agent whose form is not stated in the registry from BeBetter Med in phase 3 trials for diffuse large B-cell lymphoma, with its target not yet stated publicly.","summary":"Ifupinostat (BEBT-908, CUDC-908) is an investigational agent whose form is not stated in the registry developed by BeBetter Med. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: Ifupinostat Hydrochloride for Injection,dosage of administration:18.5mg/m\\^2,frequency and duration of administration:Medication is administered on days 1, 3, 5, 8, 10, and 12 of each cycle,with a 21-day or 42-day cycle duration. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06792253 (Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma), in diffuse large B-cell lymphoma. The largest, NCT06792253, plans to enrol 416 participants with primary completion expected 2028-12-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Ifupinostat","url":"https://clinicaltrials.gov/search?intr=BEBT-908"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["bebetter-med"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06792253"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"BEBT-908, CUDC-908","modality":"not stated (registered as a drug or biological on ClinicalTrials.gov)","mechanism":"Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ifupinostat/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"company":[{"id":"bebetter-med","kind":"company","name":"BeBetter Med","route":"/companies/bebetter-med/"}],"trial":[{"id":"nct06792253","kind":"trial","name":"Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","route":"/trials/nct06792253/"}]}}